 |
Corporate News
04-May-22
|
|
|
|
|
|
|
|
|
|
|
|
Gland Pharma announces launch of Bortezomib for Injection in US market
|
|
USed in treatment of certain types of cancer
|
|
|
|
|
|
Gland Pharma through its partner has launched Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial in the US Market. It is the bioequivalent and therapeutically equivalent to thereference listed drug (RLD), Velcade® for Injection, 3.5 mg/vial of Takeda Pharmaceuticals U.S.A., Inc.
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma.
Velcade has a market size of USD 1,172 million for the twelve months ending March 2022, according to IQVIA.
Gland Pharma's partner has received the ANDA approval for the product from U.S. Food & Drug Administration (US FDA). Gland Pharma is manufacturing and supplying this product to its partner for the US
market.
|
|
|
|
Previous News |
Stock alert: Indus Towers, Gland Pharma, Advanced Enzyme, DMart, Sapphire Foods
(
Market Commentary
-
Stock Alert
20-Jun-24
08:50
)
|
|
|
Gland Pharma Ltd up for third straight session
(
Hot Pursuit
-
31-Jul-23
13:05
)
|
|
|
Gland Pharma's Pashamylaram facility clears USFDA inspection
(
Corporate News
-
26-Sep-23
11:46
)
|
|
|
Gland Pharma Ltd leads losers in 'A' group
(
Hot Pursuit
-
27-Oct-22
15:00
)
|
|
|
Gland Pharma Ltd gains for fifth session
(
Hot Pursuit
-
11-Jun-24
13:00
)
|
|
|
Gland Pharma Ltd soars 0.86%, gains for fifth straight session
(
Hot Pursuit
-
09-Jun-23
13:00
)
|
|
|
Gland Pharma gains after receiving EIR report for Hyderabad facility from USFDA
(
Hot Pursuit
-
26-Sep-23
11:28
)
|
|
|
Gland Pharma
(
Results
-
Analysis
27-Oct-22
10:43
)
|
|
|
Gland Pharma IPO subscribed 22%
(
IPO Centre
-
IPO News
10-Nov-20
17:34
)
|
|
|
Gland Pharma receives USFDA approval for Eribulin Mesylate Injection
(
Corporate News
-
06-Apr-24
17:40
)
|
|
|
Gland Pharma slides after Q3 PAT drops 17% YoY to Rs 192 cr
(
Hot Pursuit
-
15-Feb-24
11:10
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|